What Happens When the Medicare GLP-1 Bridge Ends? The 2027 Cliff

The Medicare GLP-1 Bridge is scheduled to end on December 31, 2027. When it does, the flat $50 copay it provides for weight-loss GLP-1s disappears, and there is no guaranteed permanent program waiting to replace it. Unless Congress changes the underlying law or Medicare adopts a longer-term policy, people relying on the Bridge could face a sharp jump in out-of-pocket cost overnight, which is why this is worth planning for now rather than in late 2027. If you’re deciding whether to even start on the Bridge, the fact that it has an expiration date is part of the calculation, and having a continuation plan ready is the sensible response.

What the end date actually means

The Bridge is a time-limited Medicare demonstration, not a permanent benefit. It runs from July 1, 2026 through December 31, 2027. During that window, eligible members pay $50 a month for covered medications. After that window, the demonstration simply stops unless it’s extended or replaced.

Two things make the cliff real rather than hypothetical. First, the long-standing 2003 statute that excludes weight-loss drugs from routine Part D coverage is still on the books, so when the demonstration ends, the default rule returns. Second, a more permanent fix would require either legislation or a new policy decision, neither of which is guaranteed.

Why the jump could be steep

If the Bridge ends and nothing replaces it, someone paying $50 a month could be looking at a return to cash prices or whatever their plan allows under the standard exclusion. The gap between $50 and a brand-name cash price is large, which is what makes the transition jarring for anyone who hasn’t planned for it.

Consider a scenario where someone starts on the Bridge in 2026, does well on a covered GLP-1, and treats the $50 copay as their permanent normal. If they reach January 2028 without a plan, they may suddenly need to find several hundred dollars a month to stay on treatment, or risk stopping abruptly. Stopping a GLP-1 cold is its own problem, since appetite and weight effects tend to reverse when treatment ends.

The options that will still exist after 2027

The encouraging part is that cash-pay routes to the same molecules don’t depend on the Bridge at all, and they’ll still be there. Direct manufacturer programs and compounded GLP-1 through telehealth operate outside Medicare entirely. There’s also a longer arc worth knowing about: generic competition is coming, even if slowly. Semaglutide’s main US patent runs into the early 2030s, with generic and biosimilar versions already in development internationally, which over time should push prices down. That’s not a 2028 solution, but it shapes the longer outlook.

Where oral options fit

One reason the post-Bridge picture isn’t bleak is that lower-cost oral GLP-1s have arrived and keep expanding. Oral semaglutide has solid trial support behind it. In the PIONEER 4 trial, oral semaglutide was compared against injectable liraglutide and placebo in 711 adults with type 2 diabetes, and it was non-inferior to liraglutide on A1c while producing greater weight loss, around 4.7 kg at 26 weeks. The point isn’t the specific number, it’s that effective GLP-1 treatment increasingly comes in formats and price points beyond the four-figure branded injectables, which gives people more ways to stay on therapy after a program like the Bridge ends.

How to plan ahead now

The practical move is to treat the Bridge as a bridge, which is what it’s named for. If you’re on it or considering it, know your continuation options before you need them. That means understanding what compounded or direct cash pricing would cost you, so a 2028 transition is a planned step rather than a shock. Consider a scenario where someone on the Bridge spends 2027 quietly confirming what a cash-pay program would run for their dose. When the demonstration ends, they switch without a gap in treatment. That’s a far better outcome than discovering the cliff after falling off it.

A continuation route that doesn’t expire

Because cash-pay telehealth isn’t tied to any Medicare demonstration, it’s a natural landing spot when the Bridge ends. TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, across a program range of $179 to $1,579 depending on the medication and plan. It will be available the same way in 2028 as it is today, which is the kind of continuity a time-limited program can’t offer.

If you want to know now what your post-Bridge cost could look like, the free assessment quiz takes only a few minutes and gives you a number to plan around.

This article is for general information and is not medical or insurance advice. The future of the Medicare GLP-1 Bridge depends on policy decisions that can change. Confirm current program status with Medicare and discuss any treatment changes with a licensed healthcare provider.